Shanghai Medicilon Inc.

Intraocular Drug Delivery Barriers Intraocular drug delivery barriers mainly include tear film, cornea, conjunctiva, sclera, choroid, blood-retinal barrier, and blood-aqueous humor barrier. The fast-flowing tears in the tear film can dilute and wash away the drugs placed on the surface of the eye; the particular sandwich structure of the cornea makes it the function of limiting the penetration of lipophilic and hydrophilic drug molecules at the same time; the fast-flowing blood can quickly clear the conjunctiva, episclera, and Drugs in the choroid tissue; while the blood-aqueous humor barrier and the blood-retinal barrier together constitute the barrier system between blood vessels and the entire ocular tissue, limiting the exchange of substances between blood vessels and ocular tissues. [1] Solutions, suspensions, emulsions, gels, and ointments are common topical ophthalmic formulations. Traditional ophthalmic formulations often have low bioavailability. Most eye diseases are treate

  The eye is a highly compartmentalized organ, and its anatomical structure has many self-protective barriers, which also constitute a barrier for drug delivery. The eye is divided into an anterior segment and a posterior segment. The anterior segment includes the cornea, conjunctiva, iris, aqueous humor, and ciliary body, and the posterior segment includes the vitreous, retina, choroid, and sclera. The physiological barriers of the eye include the cornea and conjunctiva barrier, the blood aqueous humor barrier, and the blood-retinal barrier, among which the cornea and retina are barriers that are difficult for drugs to penetrate. [1] Most ophthalmic drugs sold in the market are in the form of eye drops, eye ointment and ophthalmic gel for external use, which have extremely low bioavailability and basically do not enter the posterior segment of the eye. [2] In addition to traditional ophthalmic solutions, emulsions, suspensions, gels, and ointments, increasing interest has shifted to

As an important organ of the body, the eyes are responsible for perceiving the external world. The eyes complete about 90% of the information obtained by human sensory organs from the outside world. The structure of the eye is delicate, and even a slight injury may cause structural changes, resulting in decreased or complete loss of visual function, resulting in immeasurable losses. [1] The eye has unique anatomical and physiological properties that limit the delivery of drugs to target ocular tissues/sites. Most ophthalmic drugs are administered topically in the conjunctival sac, most commonly in the form of eye drops. Affected by various physiological barriers, the ocular bioavailability of eye drops is extremely low, generally less than 5%. [4] Today, recent advances in the fields of pharmacy, biotechnology, and materials science are facilitating the development of novel ophthalmic dosage forms that provide sustained drug delivery, reduce dosing frequency, and increase the ocular bi

Topical administration is a conventional treatment for ophthalmic diseases. Common types of topical ophthalmic formulations include solutions, suspensions, emulsions, gels, and ointments, and others. However, due to the relatively precise structure of the eye, unique anatomical and biological characteristics, etc., only a small part of the drug administered locally can reach the target tissue and cannot be effectively delivered in the eye, resulting in low bioavailability of ocular drugs. Recent advances in the fields of pharmacy, biotechnology, and materials science have facilitated the development of novel ophthalmic dosage forms that can provide sustained drug delivery, reduce dosing frequency, and improve the ocular bioavailability of drugs. [2] The eye is divided into an anterior segment and a posterior segment. The anterior segment includes the cornea, conjunctiva, iris, aqueous humor, and ciliary body, and the posterior segment includes the vitreous, retina, choroid, and sclera.

On April 20, Medicilon Preclinical Research (Shanghai) LLC (MPR), a wholly-owned subsidiary of Shanghai Medicilon Inc. (Medicilon), has obtained the GLP (Good Laboratory Practice) certification of the National Medical Products Administration (NMPA) for the newly added facilities at Nanhui Park.  In addition, Medicilon obtained two GLP certification approvals for the reproductive toxicity test (Stage III) and the carcinogenicity test qualification.  Medicilon also passed the three-year regular review of NMPA drug GLP. As of now, the service area of MPR GLP services has been increased from 8 to 9, which are single and multiple dose toxicity studies (rodent), single and multiple dose toxicity studies (non-rodent), reproductive toxicity test (Stage I, II, III), genetic toxicity test (Ames, micronucleus, chromosomal aberration), local toxicity test, immunogenicity test, safety pharmacology test, toxicokinetic test, and carcinogenicity test.  The total GLP laboratory area of Medicilon increa